September 13, 2017 Licensing, IP, and Legal PR/Corporate

Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS

Basel, 13 September 2017 Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS New study combining Esbriet (pirfenidone) and nintedanib showing similar safety profile for the combination treatment to that expected for each treatment alone A second, retrospective, post-hoc, analysis suggests that treatment with Esbriet may be... Read more

September 11, 2017 Bio/Pharma/CRO

Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma

Basel, 11 September 2017 Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data for the phase III BRIM8 study, which was designed to investigate the efficacy and safety of Zelboraf® (vemurafenib) in the adjuvant (after surgery) treatment of people... Read more

September 8, 2017 Bio/Pharma/CRO

Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration

Basel, 08 September 2017 Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration Spectri study did not meet its primary endpoint of reducing mean change in geographic atrophy lesion area in patients treated with lampalizumab compared with sham treatment Safety profile was in line with... Read more

September 8, 2017 Clinical Research/Diagn.

Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress

Basel, 08 September 2017 Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress First data on new blood-based assay for measuring tumour mutational burden Two prospective studies underway to assess the potential of tumour mutational burden to predict response to certain cancer immunotherapies Roche (SIX: RO, ROG;... Read more

September 6, 2017 Uncategorized

Roche ranked again the most sustainable healthcare company in the Dow Jones Sustainability Indices

Basel, 07 September 2017 Roche ranked again the most sustainable healthcare company in the Dow Jones Sustainability Indices Roche recognised as a sustainability leader for the ninth year in a row Sustainability is an integral part of Roche’s business strategy The company performed particularly well in the categories addressing the burden of healthcare costs, ethical... Read more

September 6, 2017 Bio/Pharma/CRO Clinical Research/Diagn. PR/Corporate

Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer

Basel, 06 September 2017 Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer ALUR study shows 85% reduction in risk of disease worsening or death versus chemotherapy in patients with advanced ALK-positive NSCLC who had progressed on chemotherapy and crizotinib Roche (SIX: RO,... Read more

August 31, 2017 Clinical Research/Diagn. PR/Corporate Product Launch

Roche to present new data from its oncology portfolio at the 2017 European Society for Medical Oncology (ESMO) Congress

Basel, 31 August 2017 Roche to present new data from its oncology portfolio at the 2017 European Society for Medical Oncology (ESMO) Congress Data from 18 approved and investigational cancer medicines to be presented at ESMO 2017 Results for Zelboraf (vemurafenib) as an adjuvant treatment for BRAF V600 mutation-positive melanoma to feature in the ESMO... Read more

August 30, 2017 Acad, Gov/Utilities Microscopy

FDA approves Roche’s Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome

Basel, 30 August 2017 FDA approves Roche’s Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome Actemra/RoActemra is the first FDA-approved treatment for severe or life-threatening cytokine release syndrome induced by CAR T cell therapy CAR T cell therapy is an immunotherapy designed for the treatment of certain cancers This is the... Read more

August 30, 2017 Acad, Gov/Utilities Microscopy

FDA approves Roche’s Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome

Basel, 30 August 2017 FDA approves Roche’s Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome Actemra/RoActemra is the first FDA-approved treatment for severe or life-threatening cytokine release syndrome induced by CAR T cell therapy CAR T cell therapy is an immunotherapy designed for the treatment of certain cancers This is the... Read more

August 28, 2017 Acad, Gov/Utilities

FDA grants Priority Review for Roche’s Gazyva in previously untreated follicular lymphoma

Basel, 28 August 2017 FDA grants Priority Review for Roche’s Gazyva in previously untreated follicular lymphoma Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Gazyva® (obinutuzumab) in combination with chemotherapy followed by Gazyva... Read more